Physician profile
Ram K Puri
NPI 1174518856
$2,829.65
in general payments reported to CMS, 2019-2025
25 companies · $16.46 in 2025
The $16.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $469 · 2021: $646 · 2022: $793 · 2023: $492 · 2024: $27.45 · 2025: $16.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $609.86 | 2019-2023 | Symbicort, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $415.72 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $259.46 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $171.07 | 2019-2022 | |
| Genzyme Corporation | $162.96 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.96 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Merck Sharp & Dohme LLC | $115.72 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $111.73 | 2021-2022 | |
| Lilly USA, LLC | $105.90 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $94.63 | 2021-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $93.89 | 2021-2022 | |
| Advanced Respiratory, INC | $85.41 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $71.60 | 2021-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $57.49 | 2023 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $55.59 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $47.23 | 2019-2022 | |
| Mylan Specialty L.P. | $43.16 | 2020-2021 | |
| Harmony Biosciences LLC | $39.22 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.53 | 2022 | |
| Philips North America LLC | $22.60 | 2019 | |
| Baxter Healthcare | $20.37 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.04 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.